for assistance and reagents and to I. Inman for outstanding technical assistance. This work was supported by the McKnight Foundation (T.L.S.) and a Silvio Conti Center for Neuroscience Award from the NIMH (T.L.S. and R.H.S.). A.D. was supported by an MSTP fellowship from the NIGMS (5T32 GM07365). R.W.B. was supported by a predoctoral NSF fellowship. D.L.D. was supported by a postdoctoral Muscular Dystrophy Association fellowship.

No abstract

preschool children is significantly increased in the last decade (student t-test, p). Conclusions Data from 2013 indicate that about 30% of young children encounter the obesity problem. Therefore, children at this age already should represent the priority population for intervention strategies such as control of diet and/or physical activity. Background and aims Osteogenesis imperfecta (OI) is a disorder that leads to fragile bones and significant morbidity. The aim was to find out the prevalence of Vitamin D deficiency in children with OI. Methods In present study, 15 children with clinically severe OI on zoledronate therapy were studied. The biochemical parameters tested were Vit D level and urine DPD level along with the routine parameters like Ca, Po, ALP, and urinary calcium creatinine ratio. We used a cut-off value of 30 ng/ml for vitamin D deficiency. Also cost effectiveness of zolendronate therapy was assessed. Results Most of the OI patients were vit D deficient (80%). The mean value of vitamin D in the study was 21.89 ± 9.76 (mean ±SD), and median value was 25.49 units. This treatment in present study did not significantly increase the financial burden on the family using alternate brand of zolendronate. Conclusions High prevalence od Vitamin D deficiency in OI may be due to their less mobility and thus less sun exposure, the low vit D level can decrease their response to zolendronate treatment Vitamin D supplementation may be needed at higher doses along with oral calcium in patients with OI put on bisphosphonates therapy. Generic preparations of zoledronate do not increase the burden of therapy in patients with OI. Further studies are needed to find out long term side effects of zoledronate therapy in children. -2014-307384.748 Background In this study we aimed to investigate the relationship between maternal and neonatal 25(OH)D levels. Methods The subjects were 58 mothers and their newborns who were born between February 2012 and April 2012. Blood specimens were obtained within 72 h of birth and from mothers. Serum 25(OH)D concentrations were measured. Vitamin D deficiency was defined as serum concentrations ≤20 ng/mL. Results The mean gestational age and birth weight of preterm infants were 33.06 ± 2.2 weeks and 2125.4 ± 546 g and for term infants were 38.84 ± 1 weeks and 3470.3 ± 451 g, respectively. Sociodemographic characteristics of mothers were not significantly different between groups. PO-0077 PO-0078